Shares of Qiagen NV (NYSE:QGEN) have earned an average rating of “Hold” from the twenty-one analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $32.88.

A number of research analysts have recently commented on QGEN shares. Deutsche Bank cut shares of Qiagen from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Evercore ISI upgraded shares of Qiagen from an “in-line” rating to an “outperform” rating in a report on Thursday, November 14th. Berenberg Bank reissued a “buy” rating on shares of Qiagen in a research report on Tuesday, October 1st. Bank of America restated an “underperform” rating and issued a $28.00 target price on shares of Qiagen in a research note on Thursday, December 26th. Finally, TheStreet lowered shares of Qiagen from a “b-” rating to a “c+” rating in a research report on Friday, October 18th.

A number of institutional investors have recently modified their holdings of the business. Strs Ohio raised its stake in shares of Qiagen by 40.5% during the 4th quarter. Strs Ohio now owns 17,292 shares of the company’s stock valued at $584,000 after buying an additional 4,981 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in Qiagen during the fourth quarter worth about $77,000. Huntington National Bank raised its position in Qiagen by 21.0% during the fourth quarter. Huntington National Bank now owns 1,897 shares of the company’s stock valued at $64,000 after acquiring an additional 329 shares in the last quarter. Alpine Global Management LLC purchased a new position in Qiagen during the fourth quarter valued at approximately $348,000. Finally, Advisors Capital Management LLC raised its position in Qiagen by 8.0% during the fourth quarter. Advisors Capital Management LLC now owns 11,371 shares of the company’s stock valued at $384,000 after acquiring an additional 846 shares in the last quarter. Institutional investors own 62.59% of the company’s stock.

Shares of NYSE QGEN traded up $0.14 during midday trading on Friday, hitting $34.96. The company’s stock had a trading volume of 1,244,836 shares, compared to its average volume of 2,730,332. The company has a current ratio of 2.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The business’s 50 day moving average is $36.98 and its two-hundred day moving average is $35.47. Qiagen has a 12-month low of $25.04 and a 12-month high of $43.16. The firm has a market cap of $7.85 billion, a P/E ratio of -268.92, a price-to-earnings-growth ratio of 2.58 and a beta of 0.91.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.01. The company had revenue of $382.70 million during the quarter, compared to analysts’ expectations of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. Qiagen’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 EPS. On average, analysts predict that Qiagen will post 1.4 earnings per share for the current fiscal year.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Read More: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.